MedTrace Logo

Safety and Tolerability of Dabigatran Etexilate in Adolescents

NCT00844415 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2025-02-12

Study results available
· View outcomes & findings →

Summary

To investigate the safety and tolerability of dabigatran etexilate capsules in a small group of eight adolescent patients.

Conditions

  • Venous Thromboembolism

Interventions

DRUG

dabigatran etexilate

2.14 mg/kg BID to a max 150 mg BID

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-01
Primary Completion
2012-02-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00844415 on ClinicalTrials.gov